Fishman P H, Aloj S M, Kohn L D, Brady R O
Proc Natl Acad Sci U S A. 1976 Nov;73(11):4060-4. doi: 10.1073/pnas.73.11.4060.
Plasma membranes derived from rat thyroid tumor (1-8R) which is unresponsive to thyrotropin but is responsive to dibutyryl adenosine 3':5'-cyclic monophosphate bind less than 20% of the [125I] thyrotropin which can be bound to plasma membranes from normal rat thyroids under conditions which optimize tumor membrane binding relative to normal thyroid membranes. In addition, the binding is different from thyrotropin binding to normal thyroid membranes both in its altered sensitivity to changes in hydrogen ion concentration and in a decreased sensitivity to competition by unlabeled thyrotropin. This reduced capacity to bind [125I] thyrotropin cannot be attributed to degradation of the hormone by membrane-associated proteases. Although the supernatant phase of the thyroid tumor homogenates contains a soluble component which inhibits [125I] thyrotropin binding to thyrotropin receptors on plasma membranes, its level is the same as in homogenates of normal thyroid tissue. Trypsin digestion does not expose thyrotropin receptors in a manner analogous to that seen in normal thyroid tissue. The major ganglioside in the tumor membranes is N-acetylneuraminylgalactosylglucosylceramide and the membranes lack the N-acetylgalactosaminyltransferase required for the synthesis of more complex gangliosides. In contrast, the normal rat thyroid membranes contain more complex gangliosides such as galactosyl-N-acetylgalactosaminyl-[N-acetylneuraminyl]-galactosylglucosylceramide and N-acetylneuraminylgalactosyl-N-acetylgalactosaminyl-[N-acetylneuraminyl]-galactosylglucosyl ceramide as well as the glycosyltransferase activities required for their syntheses. Galactosyl-N-acetylgalactosaminyl-[N-acetylneuraminyl]-galactosylglucosylceramide can also be detected in normal membranes, but not in tumor membranes, by selective labeling with galactose oxidase (D-galactose: oxygen 6-oxidoreductase, EC 1.1.3.9) and [3H] sodium borohydride. These results support the hypothesis that gangliosides are important structural or functional components of thyrotropin receptors on thyroid plasma membranes.
源自大鼠甲状腺肿瘤(1-8R)的质膜对促甲状腺激素无反应,但对二丁酰腺苷3':5'-环磷酸有反应,在相对于正常甲状腺膜优化肿瘤膜结合的条件下,其结合的[125I]促甲状腺激素不到正常大鼠甲状腺质膜可结合量的20%。此外,这种结合在对氢离子浓度变化的敏感性改变以及对未标记促甲状腺激素竞争的敏感性降低方面,与促甲状腺激素与正常甲状腺膜的结合不同。这种结合[125I]促甲状腺激素能力的降低不能归因于膜相关蛋白酶对激素的降解。尽管甲状腺肿瘤匀浆的上清相中含有一种可溶性成分,可抑制[125I]促甲状腺激素与质膜上促甲状腺激素受体的结合,但其水平与正常甲状腺组织匀浆中的相同。胰蛋白酶消化不会以类似于正常甲状腺组织中所见的方式暴露促甲状腺激素受体。肿瘤膜中的主要神经节苷脂是N-乙酰神经氨酰半乳糖基葡糖基神经酰胺,且这些膜缺乏合成更复杂神经节苷脂所需的N-乙酰半乳糖胺基转移酶。相反,正常大鼠甲状腺膜含有更复杂的神经节苷脂,如半乳糖基-N-乙酰半乳糖胺基-[N-乙酰神经氨酰]-半乳糖基葡糖基神经酰胺和N-乙酰神经氨酰半乳糖基-N-乙酰半乳糖胺基-[N-乙酰神经氨酰]-半乳糖基葡糖基神经酰胺以及它们合成所需的糖基转移酶活性。通过用半乳糖氧化酶(D-半乳糖:氧6-氧化还原酶,EC 1.1.3.9)和[3H]硼氢化钠进行选择性标记,在正常膜中也可检测到半乳糖基-N-乙酰半乳糖胺基-[N-乙酰神经氨酰]-半乳糖基葡糖基神经酰胺,但在肿瘤膜中未检测到。这些结果支持了神经节苷脂是甲状腺质膜上促甲状腺激素受体重要的结构或功能成分这一假说。